/
CRBP
$10.08+$0.32 (+3.28%)prev close
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$188.8M
19M shares
52-week range
$7.12 – $20.56
22% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Change$-25.92
Corbus Pharmaceuticals Holdings, Inc.
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
www.corbuspharma.com- Employees
- 36
- IPO / List date
- Oct 24, 2014
- HQ
- NORWOOD, MA
Held by traders on TradeandTell
No one on the platform currently holds CRBP.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 346,998 | $3.3M |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2023-02-14 | 1-for-30reverse |
Recent trades on TradeandTell
No one on the platform has traded CRBP yet.
